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Cardiac magnetic resonance imagingIn this issue of the Journal of Cardiology, Ota et al. report an
important study on the association between plasma glucose level
at hospital admission and the development of microvascular
obstruction (MVO) after successful percutaneous coronary inter-
vention (PCI) in patients with ST-segment elevation myocardial
infarction (STEMI) [1]. Their study provides a new insight into the
harmful mechanisms of stress hyperglycemia after acute myocar-
dial infarction (AMI).
Hyperglycemia at admission as a risk factor after AMI
A high blood glucose level is often observed at admission in
patients with AMI irrespective of a history of diabetes mellitus.
Hyperglycemia at admission might be a marker of undiagnosed
diabetes or impaired glucose tolerance (IGT) [2], which are
common in patients with AMI [3]. On the other hand, hyperglyce-
mia is frequently observed even in patients without diabetes or IGT
[4], as stress hyperglycemia. Several studies demonstrated that
hyperglycemia at admission is associated with higher mortality
after AMI in patients with or without diabetes [4–6]. It is also
associated with a large infarct size, high incidence of congestive
heart failure, and cardiogenic shock after AMI. In non-diabetic
patients with STEMI, both elevated glucose level on admission and
glycated hemoglobin (Hb) A1c are associated with adverse
outcome [7]. Hyperglycemia at admission was mainly associated
with large infarct size and early mortality while HbA1c was
associated with long-term mortality [7], suggesting that stress
hyperglycemia and HbA1c are associated with poor outcome due
to different mechanisms.
Several mechanisms have been proposed for the harmful effects
of hyperglycemia after AMI. Association of hyperglycemia with the
activation of blood coagulation has been well studied; it could induce
a shortening of the ﬁbrinogen half-life, increase in ﬁbrinopeptide A,
fragments of pro-thrombin in factor VII, and platelet aggregation, all
of which could lead to increased activation of thrombosis
[8]. Hyperglycemia at admission is associated with increased levelsDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.10.013
http://dx.doi.org/10.1016/j.jjcc.2014.11.012
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsof inﬂammatory markers, enhanced expression of cytotoxic T-cells,
and reduced expression of cytotoxic T-lymphocyte-associated
protein 4, indicating its association with increased inﬂammatory
immune process after AMI [9]. It also could be associated with
endothelial dysfunction, oxidative stress, and possibly, abolition of
protective ischemic preconditioning [8]. The other possible mecha-
nism of harmful effects of acute hyperglycemia is microvascular
dysfunction after coronary revascularization.
Coronary microcirculation and acute hyperglycemia
Microvascular dysfunction observed after successful PCI is
highly associated with large infarct size, reduced systolic function,
higher incidence of malignant arrhythmia, heart failure [10], and
long-term mortality [11]. Thus, development of microvascular
dysfunction after coronary reperfusion, known as no reﬂow
phenomenon or MVO, is thought to be one of the factors
determining functional and clinical outcomes after AMI.
Several mechanisms are thought to be involved in the
development of microvascular dysfunction. Microemboli associat-
ed with PCI procedure is deﬁnitely a major cause of microvascular
dysfunction. Other pathological mechanisms related with its
development include microvascular plugging by neutrophils and
platelets, interstitial edema, inﬂammation, endothelial dysfunc-
tion, and oxidative stress. As described above, hyperglycemia could
enhance these factors related to development of microvascular
dysfunction. Indeed, some previous studies demonstrated that
hyperglycemia at admission is an independent predictor of
microvascular dysfunction after AMI [6,12]. The present study
by Ota et al. demonstrated the association between hyperglycemia
at admission and development of MVO using late gadolinium
enhancement – cardiovascular magnetic resonance imaging (LGE-
CMR) [1], while previous studies used myocardial contrast
echocardiography (MCE) or angiography. Ota et al. performed
LGE-CMR within 7 days after PCI in 93 patients with ﬁrst STEMI.
MVO was observed in 34 (37%) patients, and they had higher
glucose level on admission than others, whereas no differences
were observed in HbA1c and prevalence of diabetes between them.
Glucose level on admission was an independent predictor of MVO,
along with peak creatine kinase-MB and no reﬂow on angiography.
Several imaging modalities have been used to evaluate
coronary microvascular dysfunction, including ST-segment
changes on electrocardiography, coronary angiography [throm-
bolysis in myocardial infarction (TIMI) frame count or TIMI
perfusion grade], MCE, coronary Doppler ﬂow wire, pressure wire. reserved.
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methods with several advantages over others. It is a non-invasive
modality and has a high reproducibility. CMR has a high spatial
resolution, compared to MCE, to identify the infarct area and to
determine infarct size precisely. MVO area is deﬁned as the area
with hypointense core within infarct area, although the relation
between infarct area and MVO should be investigated. Thus, the
present results by Ota et al. added highly reliable new data to the
investigation on the relation between stress hyperglycemia and
development of microvascular dysfunction.
Clinical implications of the present study
As described above, microvascular dysfunction after AMI could
determine long-term comorbidity and mortality, and its preven-
tion is a critical issue. Thrombus aspiration during primary PCI
could reduce the thrombus burden and prevent microembolism. A
large-scale, randomized trial, TAPAS (Thrombus Aspiration during
Percutaneous coronary intervention in Acute myocardial infarction
Study), demonstrated that thrombus aspiration adjunctive to
primary PCI reduced the incidence of microvascular dysfunction,
evaluated as myocardial blush grade of 0 or 1, from 26.3% to 17.1%
[13]. Thrombus aspiration could be a promising method to reduce
microvascular dysfunction, but it could not fully prevent it. Other
methods are required for its prevention, and modulation of clinical
factors associated with its development should be investigated. As
demonstrated in the present study, hyperglycemia is one of these
clinical factors, and glycemic control immediately after admission
might reduce the incidence of microvascular dysfunction. Glu-
cose–insulin–potassium (GIK) infusion as an adjunct to myocardial
reperfusion was reported to be having no cardioprotective effects
and no improvement in early mortality in patients with AMI
[14]. GIK does not always correct blood glucose levels and might
worsen hyperglycemia in some cases, which might explain the
disappointing results of GIK infusion. A large-scale, prospective
study is needed to investigate whether early control of blood
glucose could have protective effects on coronary microcirculation,
which should be precisely evaluated by LGE-CMR as in the present
study.
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